Treatment Considerations for Ponatinib in Patients With CML

Opinion
Video

Expert perspectives on treatment considerations for ponatinib in patients with chronic myeloid leukemia.

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Related Content
Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.

HSCT Recipients Show Sustained Health Challenges Following Transplant

Roman Fabbricatore
March 25th 2025
Article

Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Clinical guidelines aimed at both clinicians and patients seek to educate and include both parties in clinical decision-making processes.

Highlighting Developments and Informing Treatment Planning in CLL Care

Roman Fabbricatore
March 13th 2025
Article

Clinical guidelines aimed at both clinicians and patients seek to educate and include both parties in clinical decision-making processes.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Improved Outcomes in MRD-Negative R/R B-ALL with Obe-Cel Treatment

Improved Outcomes in MRD-Negative R/R B-ALL with Obe-Cel Treatment

Ashley Chan
February 15th 2025
Article

Results from the FELIX study showed that obe-cel induces high rates of MRD-negative remission in relapsed/refractory B-ALL, leading to improved EFS and OS.

The analysis saw minimal evidence of increased relapse among patients with hematologic cancers and minimal residual disease vs those without.

UCBT Yields Excellent Efficacy Outcomes in Hematologic Malignancies

Roman Fabbricatore
February 13th 2025
Article

The analysis saw minimal evidence of increased relapse among patients with hematologic cancers and minimal residual disease vs those without.